BFA
LXRX icon

BlackRock Fund Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlackRock Fund Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$41.2M Buy
2,977,143
+508,684
+21% +$8.16M 0.01% 1804
2016
Q3 		$44.6M Buy
2,468,459
+124,460
+5% +$2M 0.01% 1658
2016
Q2 		$33.6M Buy
2,343,999
+21,886
+0.9% +$297K 0.01% 1741
2016
Q1 		$27.7M Buy
2,322,113
+129,969
+6% +$1.36M 0.01% 1797
2015
Q4 		$29.2M Sell
2,192,144
-242,905
-10% -$2.99M 0.01% 1814
2015
Q3 		$26.2M Buy
2,435,049
+141,530
+6% +$1.55M 0.01% 1826
2015
Q2 		$18.5M Buy
2,293,519
+83,948
+4% +$617K ﹤0.01% 2159
2015
Q1 		$14.6M Buy
2,209,571
+441,495
+25% +$3.01M ﹤0.01% 2234
2014
Q4 		$11.3M Buy
1,768,076
+169,339
+11% +$1.37M ﹤0.01% 2390
2014
Q3 		$15.8M Buy
1,598,737
+9,645
+0.6% +$103K ﹤0.01% 2097
2014
Q2 		$17.9M Sell
1,589,092
-136,556
-8% -$1.47M 0.01% 2095
2014
Q1 		$20.9M Buy
1,725,648
+65,246
+4% +$834K 0.01% 1973
2013
Q4 		$20.9M Buy
1,660,402
+11,480
+0.7% +$183K 0.01% 1970
2013
Q3 		$27.5M Buy
1,648,922
+205,486
+14% +$3.45M 0.01% 1756
2013
Q2 		$21.9M Buy
+1,443,436
New +$21.9M 0.01% 1799

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

BlackRock Fund Advisors's LXRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Lexicon Pharmaceuticals (LXRX) stake by 21% in Q4 2016, buying an estimated $8.16M and bringing the position to 2,977,143 shares worth $41.2M. The position accounts for 0.01% of the portfolio, ranked #1804.

BlackRock Fund Advisors first reported a position in LXRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $44.6M in Q3 2016. 146 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

  • BlackRock Fund Advisors held 2,977,143 shares of Lexicon Pharmaceuticals worth $41.2M as of Q4 2016.
  • BlackRock Fund Advisors bought 508,684 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $8.16M.
  • Lexicon Pharmaceuticals made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1804 holding.
  • BlackRock Fund Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Lexicon Pharmaceuticals position peaked at $44.6M in Q3 2016.
  • 146 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.